Phase 1 N=11 Doravirine, Rifapentine and Isoniazid Interaction
Latent Tuberculosis · Human Immunodeficiency Virus · Rifamycins Causing Adverse Effects in Therapeutic Use
Primary: Doravirine Maximum Concentration (Cmax) — 1.7; 1.3 ug/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=82 A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Lymphoma, Non Hodgkin
Primary: Number of Participants With Adverse Events in Diffuse Large B-Cell Lymphoma (DLBCL) Population — 2; 3; 5; 0 Participants
Phase 3 N=578 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression-free Survival (PFS) — 65.12; 14.32 Months — p=< 0.0001
Phase 3 N=53 Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation
Chronic Iron Overload
Primary: Overview of Number of Participants With Adverse Events — 52; 20; 14; 2 number of participants
Phase 2 N=76 High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
Multiple Myeloma
Primary: Overall Response Rate After 4 Cycles — 4; 3; 32; 21 Participants
Phase 2 N=170 Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
Major Depressive Disorder
Primary: Mean Time of Retention — 27.08; 25.84 weeks
Phase 4 N=40 Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
Hypotension · Kidney Injury
Primary: Development of Renal Injury — 0.8; 0.74 mg/dL — p=0.31
Phase 4 N=126 Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patient Undergoing Laparoscopic Bariatric Surgery
Pain, Postoperative
Primary: Total Amount of Opioids at 48 Hours — 29.5; 27.1 mg
Phase 2 N=15 Use of Pancreatic Enzymes in Short Bowel Syndrome
Short Bowel Syndrome
Primary: Change in Coefficient of Fat Absorption — 2.3 percentage of fat absorbed
Phase 1 N=18 A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
Healthy Volunteers · Chronic Kidney Disease
Primary: Effect of RBT-3 on Plasma Ferritin Levels — 2.49; 4.42; 4.90 Ratio (24 h post-infusion over baseline)
Phase 1 N=44 Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Mean Change From Time-Matched Baseline in QTcI, Individual Baseline Corrected Rate-Corrected QT Interval — -1.3; -7.7; -1.1; -2.0 msec
N/A N=1,839 Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015
Influenza, Human
Primary: Number of Seasonal Influenza A and /or B Cases by Age Group, in Panama (Using the Data Reported Via National Influenza Surveillance Program) — 448; 120; 123; 47…
N/A N=22 Music vs. No Music During Cesarean Delivery on Patient Satisfaction
Patient Satisfaction
Primary: Patient Satisfaction — 120; 116 units on a scale
Phase 4 N=36 Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure
Sepsis · Respiratory Failure · Agitation
Primary: Duration of Mechanical Ventilation — 5; 3 days — p=0.107
Phase 4 N=60 Impact of the Serratus Plane Block in Pain and the Use of Opioids in Breast Surgery
Surgery · Breast Reconstruction
Primary: Total Opioid Usage — 18.5; 30 milligrams — p=< 0.05